| Issue Date | Title | Author(s) |
| 2021-04-21 | Applying a framework to assess the impact of cardiovascular outcomes improvement research. | Sarkies, MN; Robinson, S; Briffa, T; Duffy, SJ; Nelson, M; Beltrame, J; Cullen, L; Chew, D; Smith, J; Brieger, D; Macdonald, P; Liew, D; Reid, C |
| 2015-12-10 | Benefits and resource implications of family meetings for hospitalized palliative care patients: Research protocol | Hudson, PL; Girgis, A; Mitchell, GK; Philip, J; Parker, D; Currow, D; Liew, D; Thomas, K; Le, B; Moran, J; Brand, C |
| 2021-04-23 | Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis | Kim, H; Cook, G; Goodall, S; Liew, D |
| 2020-05 | Cost-effectiveness and financial risks associated with immune checkpoint inhibitor therapy | Kim, H; Liew, D; Goodall, S |
| 2013-01-01 | Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes | Liew, D; De Abreu Lourenço, R; Adena, M; Chim, L; Aylward, P |
| 2022-06-15 | Current Issues in Health Technology Assessment of Cancer Therapies: A Survey of Stakeholders and Opinion Leaders in Australia. | Kim, H; Liew, D; Goodall, S |
| 2021-01-01 | Do family meetings for hospitalised palliative care patients improve outcomes and reduce health care costs? A cluster randomised trial. | Hudson, P; Girgis, A; Thomas, K; Philip, J; Currow, DC; Mitchell, G; Parker, D; Liew, D; Brand, C; Le, B; Moran, J |
| 2019-05-01 | Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health | Kim, H; Goodall, S; Liew, D |
| 2022-05-25 | How does the onset of physical disability or dementia in older adults affect economic wellbeing and co-payments for health care? the impact of gender. | Hu, Y; Carr, PR; Liew, D; Broder, J; Callander, EJ; McNeil, JJ |
| 2020 | The potential for early health economic modelling in health technology assessment and reimbursement decision-making | Kim, H; Goodall, S; Liew, D |
| 2021-07-14 | Reassessing the cost-effectiveness of Nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price. | Kim, H; Goodall, S; Liew, D |
